It is time to end our love affair with short-acting ß2-agonists in asthma

Michael G. Crooks, Shoaib Faruqi

Source: ERJ Open Res, 8 (4) 00353-2022; 10.1183/23120541.00353-2022
Journal Issue: October

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Abstract

Asthma is the most prevalent chronic respiratory disease worldwide and despite advances in our understanding of asthma and its treatment, it continues to be associated with significant, and largely preventable, morbidity and mortality [1, 2].



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Michael G. Crooks, Shoaib Faruqi. It is time to end our love affair with short-acting ß2-agonists in asthma. ERJ Open Res, 8 (4) 00353-2022; 10.1183/23120541.00353-2022

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.